DRKS00015217已完成不适用
Pharmacokinetic studies of Busulfan as part of conditioning therapy prior to allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis - MY-PHABUS
niversitätsklinikum Hamburg-Eppendorf0 个研究点目标入组 37 人开始时间: 2018年10月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients at the University Hospital Hamburg-Eppendorf's Department of stem cell transplantation who have been diagnosed with myelofibrosis and have an indication for allogeneic hematopoietic stem cell transplantation with previous busulfan / fludarabine conditioning therapy. (Part A) +
- •Patients at the University Hospital Hamburg-Eppendorf's Department of stem cell transplantation who have been diagnosed with myelofibrosis and have already undergone allogeneic hematopoietic stem cell transplantation with previous busulfan / fludarabine conditioning therapy. (Part B)
排除标准
- •Age <18 years,
- •Missing consent to participate in the study
研究者
相似试验
已完成
不适用
Pharmacokinetic study of intravenous busulfan in allogeneic hematopoietic stem cell transplantation for patients using intravenous busulfan and cyclophosphamide or fludarabine as conditioning regimens.Acute myeloid leukemia (AML),Acute lymphoblastic leukemia (ALL),Myelodysplastic syndrome (MDS), Chronic myeloid leukemia (CML)JPRN-UMIN000018693Kanto Study Group for Cell Therapy40
进行中（未招募）
1 期
Determine the efficacy and tolerability of appropriate doses of busulfan to administer in patients with high risk of hematological disease.hematological malignancies : Acute Myeloblastic Leukemia, Chronic Lymphoïd Leukemia, Multiple myéloma, Acute lymphoblastic leukemia.MedDRA version: 17.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10000878Term: Acute myeloblastic leukemiaSystem Organ Class: 100000004864EUCTR2014-000758-12-FRINSTITUT PAOLI CALMETTES33
已完成
2 期
Pharmacokinetic study of busulfan in allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)JPRN-UMIN000009767Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital30
已完成
2 期
Pharmacokinetic study of busulfan in allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and fludarabine as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)JPRN-UMIN000009769Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital30
已完成
2 期
A phase II trial of targeted busulfan and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation for hematological malignanciesChronic Myelogenous Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeJPRN-C000000156agoya Blood and Marrow Transplantation Group50